Endeavor BioMedicines
Last verified 2026-05-20. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $132.5Mattributed |
|---|---|
| Latest round | series-c, $132.5M, 2024-04-01attributed |
| Founded | unknown |
| Headquarters | San Diego CA |
| Industry | biotech|therapeutics|pulmonary |
| Stage | series-b+ |
| Website | endeavorbio.com |
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines for life-threatening fibrotic and oncology diseases. It serves patients with conditions such as idiopathic pulmonary fibrosis through taladegib, a Hedgehog pathway inhibitor. Its pipeline also includes ENV-501, an antibody-drug conjugate targeting fibrosis.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | series-c | $132.5M | gv |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $132.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $132.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | endeavorbio.com, read 2026-05-20 |
| Description | self-reported | endeavorbio.com, read 2026-05-20 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.